EXPOSURE-RESPONSE CHARACTERISTICS AND PREDICTORS OF EFFICACY IN MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS PATIENTS RECEIVING TOFACITINIB.

被引：0
|
作者：
Hutmacher, M. M. [1 ]
Papp, K. A. [2 ]
Lebwohl, M. [3 ]
Ito, K. [4 ]
Tan, H. [4 ]
Wolk, R. [4 ]
Mebus, C. [4 ]
Rottinghaus, S. [4 ]
Valdez, H. [5 ]
Krishnaswami, S. [4 ]
Gupta, P. [4 ]
机构：
[1] Ann Arbor Pharmacometr Grp A2PG, Ann Arbor, MI USA
[2] Prob Med Res & K Papp Clin Res Inc, Waterloo, ON, Canada
[3] Icahn Sch Med Mt Sinai, Kimberly & Eric J Waldman Dept Dermatol, New York, NY 10029 USA
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, New York, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-082
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [1] Tofacitinib exposure-response characteristics in patients with moderate to severe chronic plaque psoriasis
    Gupta, Pankaj
    Hutmacher, Matthew
    Papp, Kim
    Lebwohl, Mark
    Ito, Kaori
    Tan, Huaming
    Wolk, Robert
    Mebus, Charles
    Rottinghausi, Scott T.
    Valdez, Hernan
    Mallbris, Lotus
    Krishnaswami, Sriram
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S8 - S8
  • [2] Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis
    Hutmacher, Matthew M.
    Nestorov, Ivan
    Ludden, Tom
    Zitnik, Ralph
    Banfield, Christopher
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (02): : 238 - 248
  • [3] Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis
    Ma, Guangli
    Xie, Rujia
    Strober, Bruce
    Langley, Richard
    Ito, Kaori
    Krishnaswami, Sriram
    Wolk, Robert
    Valdez, Hernan
    Rottinghaus, Scott
    Tallman, Anna
    Gupta, Pankaj
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 587 - 596
  • [4] Predictors of response to tofacitinib or etanercept in a phase 3 randomized, noninferiority study in patients with moderate to severe chronic plaque psoriasis
    Lambert, Jo
    Strohal, Robert
    de la Cruz, Claudia
    Thaci, Diamant
    Bachelez, Herve
    Iversen, Lars
    Rottinghaus, Scott
    Tallman, Anna
    Tan, Huaming
    Berstein, Gabriel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB263 - AB263
  • [5] PREDICTORS OF RESPONSE TO TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Gooderham, Melinda
    Li, Qing
    Cichanowitz, Nicole
    La Rosa, Carmen
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 22 - 22
  • [6] Deucravacitinib exposure-response analyses in patients with moderate to severe psoriasis
    Shen, Jun
    Lovern, Mark
    Maloney, Matt
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41
  • [7] Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Gooderham, Melinda
    Li, Qing
    Cichanowitz, Nicole
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB226 - AB226
  • [8] Predictors of response to tofacitinib or etanercept in a Phase 3 randomised, non-inferiority study in patients with moderate to severe chronic plaque psoriasis
    Lambert, J.
    Strohal, R.
    de la Cruz, C.
    Thaci, D.
    Bachelez, H.
    Iversen, L.
    Rottinghaus, S.
    Tallman, A.
    Tan, H.
    Berstein, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 78 - 78
  • [9] Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis
    Korman, Abraham M.
    Hill, Dane
    Alikhan, Ali
    Feldman, Steven R.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (04) : 525 - 539
  • [10] Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling
    Liu, Yixiao
    Xu, Ling
    Wang, Xinrui
    Wu, Lijuan
    Cai, Ruifen
    Li, Lujin
    Zheng, Qingshan
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (10) : 999 - 1008
12345